Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice

Bull Exp Biol Med. 2016 Nov;162(1):56-59. doi: 10.1007/s10517-016-3544-6. Epub 2016 Nov 23.

Abstract

The effect of non-benzodiazepine anxiolytics on the ethanol-induced hyperlocomotion and behavioral sensitization was assessed in male DBA/2 mice. Selank that enhances activity of the endogenous opioid system (0.3 mg/kg, intraperitoneally), similar to the nonselective opiate receptor blocker naloxone (1.0 mg/kg, intraperitoneally), prevented the development of ethanol-induced (2.0 g/kg intraperitoneally) hyperlocomotion, in contrast to σ1-receptors agonist Afobazole (1.0 mg/kg, intraperitoneally) that did not inhibit ethanol-induced behavioral stimulation. Single dose of Selank significantly blocked manifestation of motor sensitization without affecting its formation. These findings suggest that Selank can modulate the motivational effects of ethanol.

Keywords: DBA/2 mice; Selank; behavioral sensitization; ethanol; hyperlocomotion.

MeSH terms

  • Akathisia, Drug-Induced / drug therapy*
  • Akathisia, Drug-Induced / physiopathology
  • Animals
  • Anti-Anxiety Agents / pharmacology*
  • Behavior, Animal
  • Benzimidazoles / pharmacology
  • Ethanol / pharmacology*
  • Injections, Intraperitoneal
  • Male
  • Mice
  • Mice, Inbred DBA
  • Morpholines / pharmacology
  • Naloxone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Oligopeptides / pharmacology*
  • Psychomotor Agitation / drug therapy*
  • Psychomotor Agitation / physiopathology
  • Receptors, Opioid / agonists
  • Receptors, Opioid / metabolism*

Substances

  • 2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole
  • Anti-Anxiety Agents
  • Benzimidazoles
  • Morpholines
  • Narcotic Antagonists
  • Oligopeptides
  • Receptors, Opioid
  • Naloxone
  • Ethanol
  • TP 7